SCHEMBL16508642

SCHEMBL16508642

CN/C(C)=C\c1ccccc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
TSHR P16473 2/20 0.45
ACHE P22303 1/20 0.36
HPGD P15428 2/20 0.35
KDM4E B2RXH2 6/20 0.34
GAA P10253 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
RAB9A P51151 4/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 2/20 0.33
LMNA P02545 2/20 0.33
CYP2C9 P11712 1/20 0.33
NAT1 P18440 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16372861 0.79 MAOA (0.37) ALDH1A1TSHRHPGDKDM4ERAB9A
SCHEMBL27431107 0.79 ALDH1A1 (0.50) ALDH1A1TSHRHPGDKDM4EGAA
SCHEMBL257719 0.78 ALDH1A1 (0.52) ALDH1A1TSHRACHEHPGDKDM4E
SCHEMBL14341430 0.78 LMNA (0.52) ALDH1A1TSHRHPGDGAATDP1
SCHEMBL17662655 0.75 ALDH1A1 (0.41) ALDH1A1TSHRACHEHPGDKDM4E
SCHEMBL22110382 0.75 ALDH1A1 (0.41) ALDH1A1TSHRACHEHPGDKDM4E
SCHEMBL29128997 0.74 ALDH1A1 (0.48) ALDH1A1TSHRACHEHPGDKDM4E
SCHEMBL22478581 0.74 ALDH1A1 (0.48) ALDH1A1TSHRACHEHPGDKDM4E
SCHEMBL13891036 0.74 ALDH1A1 (0.48) ALDH1A1TSHRACHEHPGDKDM4E
SCHEMBL29293295 0.74 ALDH1A1 (0.48) ALDH1A1TSHRACHEHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3625223-B1 PYRIMIDINE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2021-08-11 EP disclosed
US-20160095858-A1 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-04-07 US disclosed
US-20110294819-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294819-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, GTF3C1 ALDH1A1 3778/4885TSHR 4457/4885ACHE 4433/4885
US-20160095858-A1 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator CFTR, SCNN1B, SLC26A4 ALDH1A1 3524/4885TSHR 1187/4885ACHE 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.